Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 18.51 kDa 
• Atom Count: 1170 
• Modelled Residue Count: 139 
• Deposited Residue Count: 160 
• Unique protein chains: 2

6GB1

Crystal structure of the GLP1 receptor ECD with Peptide 11

• DOI: 10.2210/pdb6GB1/pdb

• Classification: PEPTIDE BINDING PROTEIN
• Organism(s): Homo sapiens, synthetic construct
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2018-04-13 Released: 2018-06-20 
• Deposition Author(s): Schreuder, H.A., Liesum, A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.73 Å
• R-Value Free: 0.262 
• R-Value Work: 0.205 
• R-Value Observed: 0.208 

Literature

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.

Evers, A., Bossart, M., Pfeiffer-Marek, S., Elvert, R., Schreuder, H., Kurz, M., Stengelin, S., Lorenz, M., Herling, A., Konkar, A., Lukasczyk, U., Pfenninger, A., Lorenz, K., Haack, T., Kadereit, D., Wagner, M.

(2018) J Med Chem 61: 5580-5593

• PubMed: 29879354 
• DOI: 10.1021/acs.jmedchem.8b00292
• Primary Citation of Related Structures:  
  6GB1, 6GE2, 6GDZ


• PubMed Abstract: 
  

Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design and synthesis, experimental activity, and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed us to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives, findings that can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects.

---

Organizational Affiliation: 

Sanofi-Aventis Deutschland GmbH , R&D , Industriepark Höchst , D-65926 Frankfurt am Main , Germany.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Glucagon-like peptide 1 receptor	A	128	Homo sapiens	Mutation(s): 0  Gene Names: GLP1R
Find proteins for P43220 (Homo sapiens) Explore P43220  Go to UniProtKB:  P43220
NIH Common Fund Data Resources
PHAROS:  P43220 GTEx:  ENSG00000112164

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Peptide 11	B	32	synthetic construct	Mutation(s): 0

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
HEZ	A, B	HEXANE-1,6-DIOL C6 H14 O2 XXMIOPMDWAUFGU-UHFFFAOYSA-N
SO4	A	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
AIB	B	L-PEPTIDE LINKING	C4 H9 N O2		ALA

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.73 Å
• R-Value Free: 0.262 
• R-Value Work: 0.205 
• R-Value Observed: 0.208 
• Space Group: P 4₃ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 55.55	α = 90
b = 55.55	β = 90
c = 138.83	γ = 90

Software Package:

Software Name	Purpose
BUSTER	refinement
XDS	data reduction
AutoPROC	data scaling
SCALA	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2018-04-13 
• Released Date: 2018-06-20 
Deposition Author(s): Schreuder, H.A., Liesum, A.

Revision History  

• Version 1.0: 2018-06-20
  Type: Initial release
  
• Version 1.1: 2018-07-25
  Changes: Data collection, Database references